Welcome to our dedicated page for China Pharma news (Ticker: CPHI), a resource for investors and traders seeking the latest updates and insights on China Pharma stock.
China Pharma Holdings, Inc. (NYSE American: CPHI) generates news across pharmaceuticals, medical devices, financing, and corporate actions. As a specialty pharmaceutical company focused on cardiovascular, CNS, infectious, and digestive diseases in China, its announcements often relate to product development milestones, regulatory progress, and changes in its capital structure.
News updates have covered the company’s reverse stock splits, including 1-for-10 and 1-for-5 ratios, as well as stockholder authorization for a potential reverse split of up to 1:20. These items are relevant for investors tracking share structure and listing status on the NYSE American. Company press releases also describe financing arrangements such as a Convertible Promissory Note and an at-the-market equity offering under a shelf registration statement on Form S-3.
Operational and product-related news includes the launch of an N95 medical protective mask, the listing of several drugs in the Catalogue of Medicines for People Infected with COVID-19, and regulatory milestones for key products. For example, the company has reported that its candesartan hypertension product passed the quality and efficacy consistency evaluation of generic drugs by the National Medical Products Administration of China. It has also provided updates on its Dry Eye Disease therapeutic device, including completion of third-party testing and expectations around market launch applications.
In addition, China Pharma issues news on technology transfer agreements for patented pharmaceutical inventions, such as ipragliflozin tablets and captopril microcapsules, where consideration is paid in restricted shares of common stock. Readers of the CPHI news page can review these developments to follow how the company manages its product pipeline, regulatory interactions, financing strategies, and corporate governance decisions over time.
China Pharma Holdings, Inc. (NYSE American: CPHI) has announced the acquisition of a patented therapeutic device targeting Dry Eye Disease (DED). With DED affecting 25-30% of the population in China, and 75% of those over 65, the company aims to fill a significant market gap. The DED drug market in China was valued at about RMB3.85 billion in 2021, growing at 12.4%. The company has established sales channels in over 30 hospitals, enhancing its ability to promote the new device. CEO Li Zhilin highlighted the growing need for effective DED treatments due to increased screen time and an aging population.
On December 1, 2022, China Pharma Holdings, Inc. (NYSE American: CPHI) received a notification from NYSE American regarding noncompliance with listing standards due to insufficient stockholders' equity, reported at $2.8 million as of September 30, 2022. This falls below the $4.0 million minimum required after reporting net losses for four consecutive fiscal years. If compliance is not achieved by December 15, 2023, delisting proceedings may commence. The Company remains operational and its stock will continue to trade while it seeks compliance.
On September 26, 2022, China Pharma Holdings, Inc. (NYSE American: CPHI) received a Deficiency Letter from NYSE American for failing to meet listing standards. The letter indicated that the company's stock has traded below $0.20 on average for the past 30 days, as of September 22, 2022. The company must either conduct a reverse stock split or demonstrate sustained price improvement by March 26, 2023. The notification does not impact the company’s operations or obligations under SEC regulations. CPHI aims to regain compliance with the listing standards.
On July 15, 2022, China Pharma Holdings, Inc. (NYSE American: CPHI) submitted a compliance plan to NYSE American to address stockholders' equity deficiencies identified in a June 15, 2022 letter. The company must demonstrate compliance with Section 1003(a)(iii) by December 15, 2023. CEO Zhilin Li expressed optimism, noting the NYSE's acceptance of the compliance plan. China Pharma focuses on critical health conditions in China, supported by a strong distribution network and GMP-certified products.
On June 15, 2022, China Pharma Holdings, Inc. (NYSE American: CPHI) received a noncompliance notice from NYSE American regarding its listing standards. The Company must submit a compliance plan by July 15, 2022 to address deficiencies and regain compliance by December 15, 2023, or face potential delisting. The stock will remain listed but will carry a '.BC' designation indicating noncompliance. Despite this, the notification does not affect the Company’s operations or SEC reporting obligations.
China Pharma Holdings, Inc. (CPHI) reported fiscal year 2021 results, showing a revenue decline to $9.6 million from $10.9 million in 2020, largely due to price pressure from centralized drug procurement policies. Gross margin fell to 3.7% from 18.0%, contributing to a net loss of $3.4 million. Operating loss increased to $2.9 million. The company noted challenges from COVID-19 and expressed optimism regarding Hainan Free Trade Port policies. Cash and cash equivalents rose to $4.9 million, but an audit opinion raised concerns about the company's going concern status.
China Pharma Holdings, Inc. (CPHI) reported a 17.6% revenue decline to $2.0 million for Q3 2021, down from $2.4 million in Q3 2020. This drop is attributed to national drug price reductions. The net loss decreased to $0.8 million, compared to $1.0 million a year ago, primarily due to lower selling expenses. For the nine months ended September 30, 2021, revenue was $6.8 million, also down from $7.9 million in 2020, with a net loss of $2.4 million. The company remains optimistic about growth opportunities in specialty pharma and TCM amid favorable policies.
China Pharma Holdings, Inc. (CPHI) reported a 35.9% decline in revenue to $2.4 million for Q2 2021, compared to $3.8 million in Q2 2020, primarily due to a one-time sale of COVID-19 testers in the previous year. The company incurred a net loss of $0.8 million, a drop from a net income of $0.01 million in the same period last year. However, excluding this one-time deal, sales increased 15% year-over-year. The company has repaid a significant loan, reducing future cash flow pressures. Overall, CPHI remains optimistic about opportunities in specialty pharmaceuticals and Traditional Chinese Medicine.
China Pharma Holdings, Inc. (NYSE American: CPHI) announced that its Candesartan hypertension product successfully passed bioequivalence tests. The company intends to leverage these results to apply for National Medical Products Administration (NMPA) approval in China. Chairman and CEO Zhilin Li emphasized the significant demand for Candesartan, given hypertension's global health impact. The product aims to help control high blood pressure, which affects over a billion people worldwide and is a leading cause of death. A successful NMPA approval could enhance market reach and sales opportunities for the company.
China Pharma Holdings, Inc. (NYSE American: CPHI) announced plans to launch a highly purified NMN+PQQ product after a successful pilot scale test. NMN, a derivative of niacin, is believed to improve health by replenishing NAD+ levels that decline with age, potentially aiding cardiovascular function and wellness. CEO Zhilin Li emphasized the product's alignment with their healthcare category and market demand, indicating that it could enhance revenue stability. The company plans to leverage the Hainan Free Trade Port for sales and may seek partnerships for global distribution.
FAQ
What is the current stock price of China Pharma (CPHI)?
What is the market cap of China Pharma (CPHI)?
